Steve Baker

Studies the microbiology, genetics, epidemiology and treatment of enteric infections in developing countries with an emphasis on focal pathogens that include Norovirus, Shigella spp. and Salmonella Typhi, the causative agents of diarrhea, dysentery and typhoid fever.

Allan Bradley

Is strongly focused on using genetics to discover genes involved in various biological systems, using somatic mutagenesis in mice to discover cancer genes and genetic screens in ES cells in culture.

Clare Bryant

We study Pattern Recognition Receptors, such as Toll-like receptors (TLR), in different mammalian species studying their roles in responding to both purified bacterial ligands and infection with Salmonella entericia serovar Typhimurium (in collaboration with Duncan Maskell).

Matt Cook

.Details to follow

Menna Clatworthy

Is interested in understanding how B cell activation and IgG antibody effector function is regulated in different tissues, particularly in the kidney and the gut using cellular and molecular immunology, single cells RNA Sequencing and two photon microscopy.

Gordon Dougan

Focuses on the genetic analysis of host/pathogen interactions during infection. He has worked extensively in both academia and industry, making important contributions in the field of vaccinology, working to improve vaccine delivery to poorly resourced regions. His group exploit genomic approaches to study host-pathogen interactions and the analysis of microbial populations, and manages teams working on vaccines, humanised antibodies and scale-up systems.

Ravindra Gupta

Focusses on host-pathogen and drug-pathogen interactions to inform HIV treatment and curative strategies. In particular, this includes in vitro HIV drug resistance to protease inhibitors and its implications for global scale up of antiretroviral therapy, and investigating the details of macrophage infection in clinical isolates.

Christoph Hess

T-cells belong to the adaptive arm of the immune system and play key roles in protecting the host from invading pathogens. Their metabolism directly enables and modulates specific immune functions. Our goal is to understand the molecular basis of cellular metabolism regulation and immune-function in health and disease states.

David Jayne

Evaluates immunotherapeutics in vasculitis, lupus and immune-mediated renal disease and co-ordinates the European Vasculitis Study Group (EUVAS) and multi-centre randomised controlled trials.

Nicole Kaneider

Studies the communication of innate immune cells with their environment, and is particularly interested in G protein-coupled receptors and the cellular consequences of their activation. A mutation of GPR35 has been associated with risk for inflammatory bowel disease and primary sclerosing cholangitis. It is possible that this can be corrected by pharmacological manipulation of the risk variant.

Arthur Kaser

Explores the cell and molecular biology of how risk genes conspire with environmental factors to trigger Crohn’s disease, an inflammatory bowel disease. This has revealed how endoplasmic reticulum stress colludes with autophagy defects, and unearthed an ancient enzyme which enables a metabolic cycle that balances electron import into mitochondria ‒ biochemically controlling energy metabolism and immunity.

Paul Lehner

Identifies novel genes and map intracellular pathways involved in virus:host interactions. Infected cells need to sense and respond appropriately to viral infection. In turn, viruses manipulate host cell signaling pathways to enable viral replication and evade immune recognition.

Florian Marks

With the International Vaccine Institute and other institutions, we operate field sites in 14 African and 12 Asian countries capable of conducting multi-center epidemiological field studies that provide well-characterized samples for basic research and as a platform for the conduct of clinical trials.

Nick Matheson

Uses functional proteomics to characterise novel proteins and processes targeted by viruses, such as HIV. He is particularly interested in viral and cellular regulation of amino acid metabolism in primary human CD4+ T cells, as well as other targets of the HIV accessory proteins Vpu, Nef, Vif and Vpr. Studying host-virus interactions provides key insights into both viral pathogenesis and cell biology, and suggests novel therapeutic approaches.

John McCafferty

John McCafferty capitalises on antibody phage display and other advanced in recombinant antibody technology, to address health problems in the developing world. The group has a particular focus on anti-venoms and will generate neutralising recombinant antibodies to toxic components such as ɑ-neurotoxins, metalloproteases and phospholipases.

Eoin McKinney

Investigates gene expression signatures in autoimmune diseases, specifically ANCA-associated systemic vasculitis and SLE. By collecting patient samples after therapy, a correlation of derived expression signatures and extensive clinical data allows the identification of novel disease biomarkers with both diagnostic and prognostic value.

Yorgo Modis

Our goal is to gain a mechanistic understanding at the molecular level of how the cell detects cytosolic viral RNA and how it silences viral gene expression.

Paul Kirk

Having previously made contributions to the field of statistical systems biology, my current research profile is at the intersection of precision medicine and statistical functional genomics. I am currently developing statistical and machine learning methods for the identification of clinically actionable disease subtypes.

James Nathan

Studies how cells sense and respond to their oxygen and nutrient environments, and the implications for human disease. His lab use a combination of biochemical and genetic approaches to identify new components that influence cellular responses to oxygen and metabolites. Understanding how these components function may lead to pathways that can be exploited therapeutically to combat inflammatory disease and tumour growth.

Virginia Pedicord

The human gastrointestinal tract houses a large number of microbes, collectively known as the microbiota. The Pedicord Lab seeks mechanistic insights into the influence of the microbiota on local and systemic immune responses. These will enable the development of new approaches to combat intestinal infections and inflammation.

Lalita Ramakrishnan

Studies the pathogenesis of tuberculosis and the basis of vastly different susceptibilities to this disease. To understand the mechanistic basis of mycobacterial persistence, and the mechanisms of granuloma formation and its role in tuberculosis, we developed a zebrafish model to study immunity to tuberculosis.

John Sinclair

We seek the molecular basis of viral latency and reactivation of this persistent human virus and how the host immune response combats virus disease. This could allow us to target the latent viral reservoir in patient populations.

Ken Smith

Combines genetics, genomics, immunology and clinical medicine, integrating detailed laboratory analysis of mechanisms of immune regulation with a prospective translational medicine programme in major autoimmune and inflammatory diseases. The main focus of the group is investigation of the biology underlying clinical outcome in immune-mediated disease.

Annie Speak

I am interested in how alterations in genes cause developmental or functional abnormalities in the immune system with a particular focus on cancer immunology.

David Thomas

I am a Professor of Renal Medicine and a clinical academic focused on understanding the biology of reactive oxygen species (ROS) in immunity.

Richard Timms

Develops and exploits novel genetic technologies to interrogate the ubiquitin-proteasome system. Selective protein degradation via the ubiquitin system plays a central role in infection and immunity; improved understanding will identify optimal targets for therapeutic intervention.

Chris Wallace

Develops and applies statistical genomic methods to understand the genes, cells and pathways involved in the aetiology of autoimmune diseases such as type 1 diabetes and the relationships between different autoimmune diseases. Our goal is to further the understanding of these diseases in order to help prevent and treat them.

Mark Wills

Is interested with the immunobiology of HCMV in lytic and during latent infection, and how the pathogen persists for the lifetime of its human host.